|
Patent landscape, scope, and claims: |
Scope and Claims Assessment for U.S. Patent 6,569,443 (Azalide Antibiotic Ophthalmic Depot)
U.S. Patent 6,569,443 is built around a topical ophthalmic treatment strategy for azalide antibiotics, with the core infringement theory tied to (i) topical administration to the eye and (ii) placement of the azalide in a “depot” formulation that supplies sustained drug presence in ocular tissue. The independent claim set covers both human and non-human animal treatment processes, and a set of composition claims centered on aqueous polymeric suspensions with defined osmotic pressure and ophthalmic safety constraints. Claim scope is broad on drug identity (formula-defined “R1/R2” azalide, with azithromycin as a dependent species) and broad on therapeutic use (multiple infectious ocular conditions), but it tightens on formulation attributes: depot/sustained release, aqueous polymeric suspending agent levels, and osmotic pressure (10 to 400 mOsM).
What does U.S. Patent 6,569,443 claim for eye infection treatment using a depot azalide antibiotic?
Key independent claim themes (process):
- Topical treatment of an eye by applying an azalide antibiotic in an amount effective to treat infection in ocular tissue.
- The “topically applying” is expressly defined as supplying a depot of a composition containing the azalide antibiotic on the eye.
- Duration-related limitation is present in multiple dependent claims: therapeutically effective concentrations within ocular tissue for at least 8, 12, and 18 hours.
- Depot retention is also time-bounded: depot remains for at least 30 minutes and at least 4 hours (dependent claims).
- Combination therapy is accommodated by adding an additional medicament selected from a long antibiotic/adjunct list.
Key independent claim themes (composition):
- A topical ophthalmic composition that is an aqueous polymeric suspension with:
- Water
- 0.01% to 1.0% azalide antibiotic (composition claim 16)
- 0.1% to 10% polymeric suspending agent
- osmotic pressure 10 to 400 mOsM
- “no constituents physiologically or ophthalmically harmful”
- A broader composition route exists with less constrained azalide % (0.01% to 5%) and an “ophthalmically acceptable carrier,” plus the osmotic pressure/safety exclusions (claims 20-22).
- One composition claim adds a functional depot requirement: depot capable of sustained release (claim 44).
How broad is the claim scope around “azalide antibiotic” identity and formula coverage?
Claim 3/35/36 (formula and species):
- The process claims define the azalide antibiotic by a formula (I) with R1 and R2 each independently hydrogen or methyl.
- Dependent claim 4/36 specifies the azalide as azithromycin.
Practical scope impact:
- The formula language is an identity limiter, but it is limited only to variants consistent with the R1/R2 substitutions (H or methyl). That generally reads as covering the azalide family members that meet those specific substitution patterns rather than “any macrolide.”
- Because the formula-dependent claims sit beneath the broader “azalide antibiotic” language, infringement risk for a generic entrant is highest if it uses any azalide meeting the defined formula constraints, or if it uses azithromycin specifically (covered by dependent species).
Combination add-on (additional medicaments):
- The additional medicament list is expansive across antibiotic classes and some non-antibiotic anti-inflammatories and agents (e.g., corticosteroids, NSAIDs, antihistamines).
- The list appears in both process and composition claims, implying that the depot concept plus azalide remains the centerpiece even when other actives are co-delivered.
Which eye infections and ocular conditions are explicitly covered?
Dependent use conditions appear in both human and non-human process claims:
Covered conditions (claims 2 and 34; mirrored in non-human claims 23/24/25/34):
- Conjunctivitis
- Ophthalmia neonatorum
- Trachoma
- Corneal ulcers
- Keratitis
- Keratoconjunctivitis
- Endophthalmitis
- Infectious uveitis
- Combinations of the above
Scope impact:
- The claim set does not limit to a single pathogen or indication; it is a disease-genre coverage that can map to multiple infectious ocular syndromes.
- For freedom-to-operate, the infringement question will turn less on indication labeling and more on whether the applied depot composition is used to treat one of these conditions in the claimed manner.
What duration and retention limits create the “depot” infringement hook?
There are two separate timing constructs:
1) Drug presence duration in ocular tissue
- At least 8 hours (claim 5; mirrored in non-human claim 37)
- At least 12 hours (claim 6; mirrored in non-human claim 38)
- At least 18 hours (claim 7; mirrored in non-human claim 39)
2) Depot physical retention after administration
- Depot remains for at least 30 minutes (claim 14; mirrored in non-human claim 30)
- Depot remains for at least 4 hours (claim 15; mirrored in non-human claim 31)
Scope impact:
- These limitations can be decisive in litigation because they can require pharmacokinetic and ocular retention evidence.
- Even if a product uses azithromycin and polymeric suspension, it must likely meet the depot performance envelope to trigger the narrower dependent claims.
What formulation constraints define the composition claims (osmotic pressure and polymeric suspension)?
Claim 16: aqueous polymeric suspension, tight azalide range
- Water
- Azalide antibiotic 0.01% to 1.0%
- Polymeric suspending agent 0.1% to 10%
- Osmotic pressure 10 to 400 mOsM
- No physiologically or ophthalmically harmful constituents
Claim 20-22: broader azalide range plus carrier flexibility
- Azalide antibiotic about 0.01% to about 5%
- Ophthalmically acceptable carrier
- Additional medicament allowed
- Osmotic pressure 10 to 400 mOsM
- Safety exclusion language
Claim 44: functional depot and sustained release
- Aqueous polymeric suspension
- Azalide antibiotic 0.1% to 5.0%
- Polymeric suspending agent levels 0.1% to 10%
- Osmotic pressure 10 to 400 mOsM
- No harmful constituents
- Depot capable of sustained release of azalide antibiotic
Scope impact:
- Osmotic pressure is a specific numeric constraint that may be used to differentiate competing products.
- The polymeric suspending agent range and aqueous polymeric suspension basis create a formulation class boundary distinct from liquid drops without polymeric depot behavior, and distinct from ointment-only approaches unless they satisfy “aqueous polymeric suspension” requirements for the particular claim being asserted.
- Claim 44’s “depot capable of sustained release” is functional. If a competitor argues non-sustained release, the question becomes whether its formulation meets sustained release capability in the claim interpretation.
How much of the patent is about combinations with other drugs?
Combination coverage is integrated into both:
- Treatment processes (claims 9-13, 12-13, and mirrored non-human claims)
- Composition claims (claims 17-19 and 21-22 and mirrored)
Additional medicament classes explicitly covered include:
- Antibiotics (broad list)
- Antivirals (listed by class)
- Antifungals (listed by class)
- Anesthetics (class)
- Anti-inflammatory agents (class, plus specific examples like corticosteroids and NSAIDs)
- Anti-allergic agents (class, plus specific examples)
Scope impact:
- The patent is not limited to monotherapy azithromycin.
- A competitor using azithromycin with other ocular drugs can still land within claim coverage if formulation and depot characteristics meet claim requirements.
Is there coverage for non-human animal ophthalmic treatment, and how does it expand the estate?
Yes. Claim set includes a parallel set of process claims for non-human animals:
- Applying the depot-containing azylide antibiotic topically to a non-human animal’s eye to treat ocular infection (claim 23)
- Mammal limitation and species list (claim 24/25):
- cows, sheep, horses, pigs, goats, rabbits, dogs, cats
- Mirrors the depot aqueous polymeric suspension (claim 26)
- Mirrors additional medicament list (claim 27/28)
- Mirrors depot composition types including suspensions/ointments/inserts (claim 29)
- Mirrors retention and duration constraints:
- depot remains at least 30 minutes and at least 4 hours (claims 30-31)
- ocular tissue concentration at least 8/12/18 hours (claims 37-39)
- Mirrors covered ocular conditions (claim 34)
Commercial/legal impact:
- For veterinary ophthalmic product strategies, this expands enforcement leverage beyond human-only market entrants.
- For human generic defense, non-human claims can still matter in licensing negotiations and in some portfolio strategies, but they usually increase the estate’s deterrence breadth.
What are the key independent vs dependent claim “tiers” that matter for enforcement?
Tier 1 (broadest anchors)
- Process: topical depot-based treatment of an eye with an azalide antibiotic in effective amount (claim 1, and analogous non-human claim 23)
- Composition: aqueous polymeric suspension with defined osmotic pressure and azalide/polymer ranges (claim 16) and broader carrier-based compositions with similar osmotic pressure and safety constraints (claims 20-22)
- Functional depot sustained release composition claim (claim 44)
Tier 2 (identity and duration tightening)
- Azalide identity to formula (I) with R1/R2 = H/methyl (claims 3/35)
- Azithromycin species (claims 4/36)
- Ocular tissue concentration duration thresholds (claims 5-7/37-39)
Tier 3 (depot retention + composition sub-type + combination)
- Depot retention after administration (claims 14-15/30-31)
- Depot vehicle forms (claims 11: aqueous suspensions, ointments, inserts)
- Additional medicament presence (claims 9-13, 12-13; claims 17-19; claims 20-22)
Litigation posture implication:
- A plaintiff can often plead around defendants by selecting the best-matching claim tier based on available evidence: chemistry and formulation testing supports composition claims; residence time and ocular concentration data supports duration/retention dependent process claims.
What does a competitor have to avoid to reduce risk of infringing U.S. 6,569,443?
Based on the claim language provided, the largest practical risk drivers are:
-
Azalide antibiotic usage meeting formula constraints (or azithromycin specifically)
- Using azithromycin in an ophthalmic depot concept is the most direct match.
-
Depot characterization
- Claims explicitly require supplying a depot of a composition on the eye and, for some dependent claims, depot retention duration.
-
Performance thresholds
- Therapeutically effective concentration within ocular tissue for at least 8/12/18 hours (depending on which dependent claim is asserted).
-
Formulation envelope for composition claims
- Osmotic pressure 10 to 400 mOsM.
- Aqueous polymeric suspension and polymer range (0.1% to 10%).
- Azalide concentration ranges vary by claim (0.01%-1.0% vs 0.01%-5% vs 0.1%-5%).
Design-around levers that map directly to language:
- Change osmotic pressure outside 10-400 mOsM for formulations that aim to avoid composition claims with that numeric limitation.
- Use a non-depot vehicle or formulation that does not qualify as a depot capable of sustained release, and that fails retention/time-based dependent claims.
- Use a different antibiotic class not captured by the “azalide antibiotic” definition as constrained by formula (I).
How does the claim structure support multiple infringement theories (process vs formulation)?
The estate supports at least three distinct enforcement angles:
-
Direct product formulation infringement
- The composition claims can be asserted without proving exactly how a clinician applies the formulation if the product is sold for topical ocular use that matches the formulation attributes.
-
Method-of-use infringement
- The process claims center on applying the depot-containing formulation and achieving time-based ocular exposure.
- This shifts proof toward pharmacokinetics, residence time, and intended therapeutic use conditions.
-
Combination regimen infringement
- Dependent claims cover additional medicaments. This means a multi-drug ocular regimen can still trigger infringement even if the defendant tries to characterize the product as a combination therapy rather than depot azithromycin alone.
What additional patent landscape questions does U.S. 6,569,443 raise for freedom-to-operate and licensing?
This patent is formulation- and use-focused; that typically sits in a dense ecosystem with:
- Earlier azalide chemistry patents (drug substance).
- Later formulation patents (depot vehicles, polymers, osmolality targets).
- Additional method patents (duration of ocular exposure, specific treatment regimens, patient subsets).
However, without the rest of the portfolio data (continuations, related assignees, prosecution history, and co-owned family members), it is not possible to produce a complete landscape map for all claims, jurisdictions, and related family members from the single patent number alone.
Key Takeaways
- U.S. Patent 6,569,443 is anchored on topical ophthalmic depot delivery of an azalide antibiotic to treat specified infectious ocular conditions.
- The claim set includes both human and non-human (mammal species listed) treatment processes and multiple aqueous polymeric suspension composition claims.
- Core formulation constraints include osmotic pressure 10-400 mOsM, polymeric suspending agent 0.1-10%, and defined azalide concentration ranges that vary by claim.
- Enforcement leverage is strongest where accused products achieve sustained ocular tissue concentrations for 8/12/18 hours and/or where the depot remains on the eye for 30 minutes to 4 hours.
- Combination therapy is explicitly supported, increasing coverage against depot-based azithromycin regimens paired with additional ocular medicaments.
FAQs
-
Does U.S. 6,569,443 cover azithromycin depot eye drops even if no “insert” is used?
Yes, depending on the exact formulation and depot performance. The composition claims cover aqueous polymeric suspensions and depot capable of sustained release.
-
Is osmotic pressure a required element for all composition claims in U.S. 6,569,443?
The provided composition claims include an osmotic pressure limit of 10 to 400 mOsM for both the aqueous polymeric suspension and broader carrier-based compositions.
-
Can a product that uses azithromycin avoid the process claims by failing the duration thresholds?
Potentially. The dependent process claims expressly require ocular tissue exposure durations (8/12/18 hours) and depot retention (30 minutes/4 hours).
-
Does the patent require treatment of a specific microorganism?
No. The claims list ocular disease conditions (conjunctivitis, keratitis, trachoma, etc.), not specific pathogens.
-
Is veterinary ophthalmic use included in U.S. 6,569,443?
Yes. The process claims cover topical depot treatment for non-human mammals, with species examples including dogs and cats.
More… ↓
⤷ Start Trial
|
